Literature DB >> 22363135

Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.

Xiang-Liang Zhang1, An-Bin Hu, Shu-Zhong Cui, Hong-Bo Wei.   

Abstract

AIM: To observe the synergistic effects of hyperthermia in oxaliplatin-induced cytotoxicity in human colon adenocarcinoma Lovo cells.
METHODS: The human colon adenocarcinoma cell line Lovo was obtained from Sun Yat-Sen University. Cells were sealed with parafilm and placed in a circulating water bath, and was maintained within 0.01 °C of the desired temperature (37 °C, 39 °C, 41 °C, 43 °C and 45 °C). Thermal therapy was given alone to the negative control group while oxaliplatin was administered to the treatment group at doses of 12.5 μg/mL and 50 μg/mL. Identification of morphological changes, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry and Western blotting were used to investigate the effect of thermochemotherapy on human colon adenocarcinoma Lovo cells, including changes in the signal pathway related to apoptosis.
RESULTS: A temperature-dependent inhibition of cell growth was observed after oxaliplatin exposure, while a synergistic interaction was detected preferentially with sequential combination. Thermochemotherapy changed the morphology of Lovo cells, increased the inhibition rate of the Lovo cells (P < 0.05) and enhanced cellular population in the G₀/G₁ phase (16.7% ± 4.8 % in phase S plus 3.7% ± 2.4 % in phase G₂/M, P < 0.05). Thermochemotherapy increased apoptosis through upregulating p53, Bax and downregulating Bcl-2. Protein levels were elevated in p53, Bax/Bcl-2 in thermochemotherapy group as compared with the control group (P < 0.05).
CONCLUSION: Thermochemotherapy may play an important role in apoptosis via the activation of p53, Bax and the repression of Bcl-2 in Lovo cells.

Entities:  

Keywords:  Colorectal cancer; Mitochondrial apoptotic pathway; Oxaliplatin; Thermochemotherapy

Mesh:

Substances:

Year:  2012        PMID: 22363135      PMCID: PMC3281221          DOI: 10.3748/wjg.v18.i7.646

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.

Authors:  Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thierry Conroy; Antoine Adenis; Roger Faroux; Christine Rebischung; Loic Bergougnoux; Leila Kockler; Jean-Yves Douillard
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 2.  More is less -- combining targeted therapies in metastatic colorectal cancer.

Authors:  Cornelis J A Punt; Jolien Tol
Journal:  Nat Rev Clin Oncol       Date:  2009-12       Impact factor: 66.675

3.  A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics.

Authors:  Yi Hong; Thomas Downey; Kong Weng Eu; Poh Koon Koh; Peh Yean Cheah
Journal:  Clin Exp Metastasis       Date:  2010-02-09       Impact factor: 5.150

4.  Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.

Authors:  Sara Nannizzi; Gareth J Veal; Elisa Giovannetti; Valentina Mey; Simona Ricciardi; Christopher J Ottley; Mario Del Tacca; Romano Danesi
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-18       Impact factor: 3.333

5.  Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells.

Authors:  Huei-Fang Liu; Huai-Chin Hu; Jui-I Chao
Journal:  Chem Biol Interact       Date:  2010-08-12       Impact factor: 5.192

6.  Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis.

Authors:  Ying Xin Wang; Xiao Yan Zhang; Bao Feng Zhang; Chang Qing Yang; Xi Mei Chen; Heng Jun Gao
Journal:  J Dig Dis       Date:  2010-02       Impact factor: 2.325

7.  Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.

Authors:  Nour A Obeidat; Françoise G Pradel; Ilene H Zuckerman; Sylvain DeLisle; C Daniel Mullins
Journal:  Am J Geriatr Pharmacother       Date:  2009-12

8.  Inhibition of NF-kappaB by combination therapy with parthenolide and hyperthermia and kinetics of apoptosis induction and cell cycle arrest in human lung adenocarcinoma cells.

Authors:  Sachiko Hayashi; Hiroaki Sakurai; Akio Hayashi; Yukie Tanaka; Masanori Hatashita; Hiroki Shioura
Journal:  Int J Mol Med       Date:  2010-01       Impact factor: 4.101

9.  Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.

Authors:  J Yang; J Parsons; N H Nicolay; S Caporali; C F Harrington; R Singh; D Finch; S D'Atri; P B Farmer; P G Johnston; W G McKenna; G Dianov; R A Sharma
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

10.  Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.

Authors:  Jairam Vanamala; Lavanya Reddivari; Sridhar Radhakrishnan; Chris Tarver
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

View more
  2 in total

1.  MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened.

Authors:  Xiang-Liang Zhang; Hui-Juan Shi; Ji-Ping Wang; Hong-Sheng Tang; Shu-Zhong Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Narrow line between benefit and harm: Additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells.

Authors:  Vaidotas Cesna; Arturas Sukovas; Aldona Jasukaitiene; Rima Naginiene; Giedrius Barauskas; Zilvinas Dambrauskas; Saulius Paskauskas; Antanas Gulbinas
Journal:  World J Gastroenterol       Date:  2018-03-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.